ArticleJournal of veterinary internal medicine2026
Urinary neutrophil gelatinase-associated lipocalin in dogs: accuracy of a novel rapid test and biomarker behavior across clinical settings.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary neutrophil gelatinase-associated lipocalin (uNGAL) has emerged as an early marker of acute kidney injury (AKI) in dogs, but its measurement by ELISA is laborious in clinical practice. HYPOTHESIS/
objectivesAssess the performance of a novel point-of-care (POC) uNGAL assay for early detection of AKI in dogs and evaluate the clinical utility of uNGAL in differentiating AKI from other urinary conditions in dogs. ANIMALS: Urine supernatants from 200 client-owned dogs were collected and grouped as follows: healthy, chronic kidney disease (CKD), AKI (including AKI on CKD), urinary tract infections, urolithiasis, and extrarenal inflammatory diseases. Dogs then were classified by the presence (n = 39) or absence (n = 161) of AKI for calculation of diagnostic performance.
methodsUrinary NGAL was measured using the Dog NGAL ELISA Kit (Bioporto) as the existing test and the "PRIMA Veterinary-KI screening test" (PRIMA Lab) as an index test.
resultsAt the optimized cut-off of 20 ng/mL for the POC device, a sensitivity of 97.3% (95%CI, 85.8-99.9) and a specificity of 66.3% (95%CI, 58.4-73.5) for diagnosing AKI were found. For the ELISA, a sensitivity of 97.3% (95%CI, 85.8-99.9) and a specificity of 80.4% (95%CI, 73.4-86.2) were found. Cohen's kappa coefficient (κ = 0.82) indicated an excellent agreement between methods. CONCLUSIONS AND CLINICAL IMPORTANCE: With both methods, uNGAL showed moderate specificity and excellent sensitivity for the diagnosis of AKI. The POC device represents a clinically relevant diagnostic tool for screening AKI in patients at risk, given excellent agreement with the existing test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.